Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas

Published by: BioSeeker Group AB

Published: Jun. 12, 2007 - 430 Pages

Table of Contents

1 Executive Summary

2 Methodologies

3 Table of Contents

3.1 List of Figures

3.2 List of Tables

3.3 List of Boxes

4 Antibody Drug Target Analysis in Oncology: What and Where Are We Targeting?

5 Antibody Drug Targets by Molecular Function

5.1 Carboxypeptidase Activity Targets

5.2 Catalytic Activity Targets

5.3 Cell Adhesion Molecule Activity Targets

5.4 Chaperone Activity Targets

5.5 Chemokine Activity Targets

5.6 Cofactor Binding Targets

5.7 Complement Activity Targets

5.8 Cytokine Activity Targets

5.9 DNA Topoisomerase Activity Targets

5.10 Extracellular Matrix Structural Constituent Targets

5.11 G-protein Coupled Receptor Activity Targets

5.12 Growth Factor Activity Targets

5.13 Hormone Activity Targets

5.14 Hydrolase Activity Targets

5.15 Intracellular Ligand-gated Ion Channel Activity Targets

5.16 Metallopeptidase Activity Targets

5.17 MHC Class I Receptor Activity Targets

5.18 Molecular Function Unknown Targets

5.19 Oxidoreductase Activity Targets

5.20 Peptide Hormone Targets

5.21 Protease Inhibitor Activity Targets

5.22 Protein Binding Targets

5.23 Receptor Activity Targets

5.24 Receptor Binding Targets

5.25 Receptor Signaling Complex Scaffold Activity Targets

5.26 Receptor Signaling Protein Tyrosine Phosphatase Activity Targets

5.27 RNA-directed DNA polymerase Activity Targets

5.28 Serine-type Peptidase Activity Targets

5.29 T Cell Receptor Activity Targets

5.30 Translation Regulator Activity Targets

5.31 Transmembrane Receptor Activity Targets

5.32 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets

5.33 Transporter Activity Targets

5.34 Unclassified Targets

6 Antibody Drugs Targeting Signaling Pathways

6.1 Alpha6 Beta4 Integrin Signaling Pathway

6.1.1 Description of Pathway

6.1.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

6.2 Androgen Receptor Signaling Pathway

6.2.1 Description of Pathway

6.2.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

6.3 B Cell Receptor Signaling Pathway

6.3.1 Description of Pathway

6.3.2 Antibody Drugs by Target, Developmental Stage and Cancer Type

6.4 EGFR1 Signaling Pathway

6.4.1 Description of Pathway

6.4.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

6.5 IL-2 Signaling Pathway

6.5.1 Description of Pathway

6.5.2 Antibody Drugs by Target, Developmental Stage and Cancer Type

6.6 IL-4 Signaling Pathway

6.6.1 Description of Pathway

6.6.2 Antibody Drugs by Target, Developmental Stage and Cancer Type

6.7 IL-6 Signaling Pathway

6.7.1 Description of Pathway

6.7.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

6.8 Kit Receptor Signaling Pathway

6.8.1 Description of Pathway

6.8.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

6.9 Notch Signaling Pathway

6.9.1 Description of Pathway

6.9.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

6.10 T Cell Receptor Signaling Pathway

6.10.1 Description of Pathway

6.10.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

6.11 TGF-beta Receptor Signaling Pathway

6.11.1 Description of Pathway

6.11.2 Antibody Drugs byTarget, Developmental Stage, and Cancer Type

6.12 TNF-alpha Signaling Pathway

6.12.1 Description of Pathway

6.12.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

6.13 Wnt Signaling Pathway

6.13.1 Description of Pathway

6.13.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

7 Antibodies Targeting Cancer Stem Cells

8 Targets of Antibody Conjugates

9 Antibody Drug Targets by Three Major Non Immunological Therapeutic Effects

9.1 Anti-Angiogenesis

9.2 Apoptosis

9.3 Protein Kinase Inhibitors

10 Antibody Targets and Drugs by Cancer Indications

10.1 Basal Cell Cancer

10.2 Biliary Cancer

10.3 Bladder Cancer

10.4 Bone Cancer

10.5 Brain Cancer

10.6 Breast Cancer

10.7 Cervical Cancer

10.8 Cervical Dysplasia

10.9 Colorectal Cancer

10.10 Endometrial Cancer

10.11 Esophageal Cancer

10.12 Fallopian Tube Cancer

10.13 Gastrointestinal Cancers

10.14 Head and Neck Cancer

10.15 Leukemias

10.16 Liver Cancer

10.17 Lung Cancers

10.18 Lymphomas

10.19 Melanoma

10.20 Mesothelioma

10.21 Myelodysplastic syndrome

10.22 Myelomas

10.23 Nasopharyngeal Cancer

10.24 Oesophageal Cancer

10.25 Ovarian Cancer

10.26 Pancreatic Cancer

10.27 Peritoneal Cancer

10.28 Prostate Cancer

10.29 Renal Cancers

10.30 Sarcomas

10.31 Thyroid Cancer

11 Expression Profiles of Antibody Drug Targets

11.1 Human Tissues and Cancer Tissues

11.2 Cancer Lines and Cells

12 Leukemia: An Introduction

12.1 Leukemia Disease Definitions

12.1.1 The Lymphoid Malignancies

12.1.2 The Myeloid Malignancies

12.2 Etiology & Pathophysiology of Leukemia

12.2.1 The Lymphoid Malignancies

12.2.2 The Myeloid Malignancies

12.3 Epidemiology of Leukemia

12.4 Prognosis of Leukemia

12.4.1 The Lymphoid Malignancies

12.4.2 The Myeloid Malignancies

13 Current Treatment Strategies of Leukemia

13.1 The Lymphoid Malignancies

13.2 The Myeloid Malignancies

14 Progress in Current Leukemia Treatment Strategies

14.1 The Lymphoid Malignancies

14.2 The Myeloid Malignancies

15 Key Therapeutic Strategies for Future Leukemia Therapies

15.1 Therapeutic type, Targets & Mechanisms

16 Competitive Landscape in Leukemia Drug Development: The Late Stage Pipeline

16.1 The Lymphoid Malignancies

16.2 The Myeloid Malignancies

17 Current Leukemia Drug Development: The Early Stage Pipeline

18 The Myeloid Malignancies

18.1 The Lymphoid Malignancies

19 Lymphoma: An Introduction

19.1 Disease Definition

19.2 Etiology & Pathophysiology

19.3 Epidemiology

20 Current Lymphoma Treatment Strategies

20.1 Hodgkin's Disease

20.1.1 Radiation Therapy

20.1.2 Chemotherapy

20.1.3 Transplantation

20.1.4 Treatment Option Overview

20.2 Non-Hodgkin's Lymphoma

20.2.1 Radiation Therapy

20.2.2 Chemotherapy

20.2.3 Immunotherapy

20.2.4 Bone Marrow and Peripheral Blood Transplants Watch and Wait

20.2.5 Treatment Option Overview

20.3 Prognosis

20.3.1 Hodgkin's Disease

20.3.2 Non-Hodgkin

21 Progress in Current Lymphoma Treatment Strategies

21.1 HODGKIN

21.2 NON-HODGKIN

21.3 Rituxan

21.4 Bexxar

21.5 Zevalin

22 Key Therapeutic Lymphoma Strategies

22.1 Antibodies & Immunostimulation 350

22.2 Small molecules: Apoptosis inducers & Kinase inhibitors

23 Competitive Landscape in Lymphoma Drug Development: The Late Stage Pipeline _ 363

24 Current Lymphoma Drug Development: The Early Stage Pipeline

25 Disclaimer

26 Drug Index

27 Company Index

28 Appendix I: Antibody Targets by Companies

29 Appendix II: Drugs Approved for the Treatment of Leukemia: A Historical Perspective

30 Appendix III: Selected Companies - Anticancer Pipelines

Accentia BioPharmaceuticals

Biogen Idec

Cell Therapeutics

Cephalon

Chiron Corporation (Now Novartis)

Eli Lilly

Favrille

Genentech

Genitope Corporation

Genmab

Genta

GlaxoSmithKline

Immunomedics

Inex Pharmaceuticals

Millennium Pharmaceuticals

Protein Design Labs

Roche

Sanofi-Aventis

Seattle Genetics

Wyeth

3.1 List of Figures

Figure 1: Antibody Pipeline Maturity by Molecular Function Classes of Targets 1(3)

Figure 2: Antibody Pipeline Maturity by Molecular Function Classes of Targets 2(3)

Figure 3: Antibdody Pipeline Maturity by Molecular Function Classes of Targets 3(3)

Figure 4: Pipeline Maturation of Carboxypeptidase Activity Targets

Figure 5: Number of Antibody Drugs per Cancer Indication and Carboxypeptidase Activity Target

Figure 6: Pipeline Maturation of Catalytic Activity Targets

Figure 7: Number of Antibody Drugs per Cancer Indication and Catalytic Activity Target

Figure 8: Pipeline Maturation of Cell Adhesion Molecule Activity Targets

Figure 9: Number of Antibody Drugs per Cancer Indication and Cell Adhesion Molecule Activity Target

Figure 10: Pipeline Maturation of Chaperone Activity Targets

Figure 11: Number of Antibody Drugs per Cancer Indication and Chaperone Activity Target

Figure 12: Pipeline Maturation of Chemokine Activity Targets

Figure 13: Number of Antibody Drugs per Cancer Indication and Chemokine Activity Target

Figure 14: Pipeline Maturation of Cofactor Binding Targets

Figure 15: Number of Antibody Drugs per Cancer Indication and Cofactor Binding Target

Figure 16: Pipeline Maturation of Complement Activity Targets

Figure 17: Number of Antibody Drugs per Cancer Indication and Complement Activity Target

Figure 18: Pipeline Maturation of Cytokine Activity Targets

Figure 19: Number of Antibody Drugs per Cancer Indication and Cytokine Activity Target

Figure 20: Pipeline Maturation of DNA Topoisomerase Activity Targets

Figure 21: Number of Antibody Drugs per Cancer Indication and DNA Topoisomerase Activity Target

Figure 22: Pipeline Maturation of Extracellular Matrix Structural Constituent Targets

Figure 23: Number of Antibody Drugs per Cancer Indication and Extracellular Matrix Structural Constituent Target

Figure 24: Pipeline Maturation of G-protein Coupled Receptor Activity Targets

Figure 25: Number of Antibody Drugs per Cancer Indication and Extracellular G-protein Coupled Receptor Activity Target

Figure 26: Pipeline Maturation of Growth Factor Activity Targets

Figure 27: Number of Antibody Drugs per Cancer Indication and Extracellular Growth Factor Activity Target

Figure 28: Pipeline Maturation of Hormone Activity Targets

Figure 29: Number of Antibody Drugs per Cancer Indication and Hormone Activity Target

Figure 30: Pipeline Maturation of Hydrolase Activity Targets

Figure 31: Number of Antibody Drugs per Cancer Indication and Hydrolase Activity Target

Figure 32: Pipeline Maturation of Ligand-gated Ion Channel Activity Targets

Figure 33: Number of Antibody Drugs per Cancer Indication and Intracellular Ligand-gated Ion Channel Activity Target

Figure 34: Pipeline Maturation of Metallopeptidase Activity Targets

Figure 35: Number of Antibody Drugs per Cancer Indication and Intracellular Metallopeptidase Activity Target60

Figure 36: Pipeline Maturation of MHC Class I Receptor Activity Targets

Figure 37: Number of Antibody Drugs per Cancer Indication and MHC Class I Receptor Activity Target

Figure 38: Pipeline Maturation of Molecular Function Unknown Targets

Figure 39: Number of Antibody Drugs per Cancer Indication and Molecular Function Unknown Target

Figure 40: Pipeline Maturation of Oxidoreductase Activity Targets

Figure 41: Number of Antibody Drugs per Cancer Indication and Oxidoreductase Activity Target

Figure 42: Pipeline Maturation of Peptide Hormone Targets

Figure 43: Number of Antibody Drugs per Cancer Indication and Peptide Hormone Target

Figure 44: Pipeline Maturation of Protease inhibitor Activity Targets

Figure 45: Number of Antibody Drugs per Cancer Indication and Protease Inhibitor Activity Target

Figure 46: Pipeline Maturationof Protein Binding Targets

Figure 47: Number of Antibody Drugs per Cancer Indication and Protein Binding Target

Figure 48: Pipeline Maturation of Receptor Activity Targets 1 (2)

Figure 49: Number of Antibody Drugs per Cancer Indication and Receptor Activity Target 1(2)

Figure 50: Pipeline Maturation of Receptor Activity Targets 2 (2)

Figure 51: Number of Antibody Drugs per Cancer Indication and Receptor Activity Target 2(2)

Figure 52: Pipeline Maturationof Receptor Binding Targets

Figure 53: Number of Antibody Drugs per Cancer Indication and Receptor Binding Target

Figure 54: Pipeline Maturation of Receptor Signaling Complex Scaffold Activity Targets

Figure 55: Number of Antibody Drugs per Cancer Indication and Receptor Signaling Complex Scaffold Activity Target

Figure 56: Pipeline Maturation of by Receptor Signaling Protein Tyrosine Phosphatase Activity Targets

Figure 57: Number of Antibody Drugs per Cancer Indication and Receptor Signaling Protein Tyrosine Phosphatase Activity Target

Figure 58: Pipeline Maturation of RNA-directed DNA polymerase Activity Targets

Figure 59: Number of Antibody Drugs per Cancer Indication and RNA-directed DNA polymerase Activity Target

Figure 60: Pipeline Maturation of Serine-type Peptidase Activity Targets

Figure 61: Number of Antibody Drugs per Cancer Indication and RNA Serine-type Peptidase Activity Target

Figure 62: Pipeline Maturation of T cell Receptor Activity Targets

Figure 63: Number of Antibody Drugs per Cancer Indication and T cell Receptor Activity Target

Figure 64: Pipeline Maturation of Translation Regulator Activity Targets

Figure 65: Number of Antibody Drugs per Cancer Indication and Translation Regulator Activity Target

Figure 66: Pipeline Maturation of Transmembrane Receptor Activity Targets

Figure 67: Number of Antibody Drugs per Cancer Indication and Transmembrane Receptor Activity Target

Figure 68: Pipeline Maturation of Transmembrane Receptor Protein Tyrosine Kinase Activity Targets

Figure 69: Number of Antibody Drugs per Cancer Indication and Transmembrane Receptor Protein Tyrosine Kinase Activity Target

Figure 70: Pipeline Maturation of Transporter Activity Targets

Figure 71: Number of Antibody Drugs per Cancer Indication and Transporter Activity Target

Figure 72: Pipeline Maturation of Unclassified Targets

Figure 73: Number of Antibody Drugs per Cancer Indication and Unclassified Target

Figure 74: Antibody Pipeline Comparison of Targeted Signaling Pathways in Oncology

Figure 75: Pipeline Maturation of Immunoconjugated Antibody Targets

Figure 76: Number of Immunoconjugated Antibody Drugs per Cancer Indication and Target

Figure 77: Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways.

3.2 List of Tables

Table 1: Molecular Functions versus Oncology Antibody Drug Targets

Table 2: Cancer Antibody Pipeline Listed by Carboxypeptidase Activity Targets

Table 3: Cancer Antibody Pipeline Listed by Catalytic Activity Targets

Table 4: Cancer Antibody Pipeline Listed by Cell Adhesion Molecule Activity Targets

Table 5: Cancer Antibody Pipeline Listed by Chaperone Activity Targets

Table 6: Cancer Antibody Pipeline Listed by Chemokine Activity Targets

Table 7: Cancer Antibody Pipeline Listed by Cofactor Binding Targets

Table 8: Cancer Antibody Pipeline Listed by Complement Activity Targets

Table 9: Cancer Antibody Pipeline Listed by Cytokine Activity Targets

Table 10: Cancer Antibody Pipeline Listed by DNA Topoisomerase Activity Targets

Table 11: Cancer Antibody Pipeline Listed by Extracellular Matrix Structural Constituent Targets

Table 12: Cancer Antibody Pipeline Listed by G-protein Coupled Receptor Activity Targets

Table 13: Cancer Antibody Pipeline Listed by Growth Factor Activity Targets

Table 14: Cancer Antibody Pipeline Listed by Hormone Activity Targets

Table 15: Cancer Antibody Pipeline Listed by Hydrolase Activity Targets

Table 16: Cancer Antibody Pipeline Listed by Intracellular Ligand-gated Ion Channel Activity Targets

Table 17: Cancer Antibody Pipeline Listed by Metallopeptidase Activity Targets

Table 18: Cancer Antibody Pipeline Listed by MHC Class I Receptor Activity Targets

Table 19: Cancer Antibody Pipeline Listed by Molecular Function Unknown Targets

Table 20: Cancer Antibody Pipeline Listed by Oxidoreductase Activity Targets

Table 21: Cancer Antibody Pipeline Listed by Peptide Hormone Targets

Table 22: Cancer Antibody Pipeline Listed by Protease inhibitor Activity Targets

Table 23: Cancer Antibody Pipeline Listed by Protein Binding Targets

Table 24: Cancer Antibody Pipeline Listed by Receptor Activity Targets

Table 25: Cancer Antibody Pipeline Listed by Receptor Binding Targets

Table 26: Cancer Antibody Pipeline Listed by Receptor Signaling Complex Scaffold Activity Targets

Table 27: Cancer Antibody Pipeline Listed by Receptor Signaling Protein Tyrosine Phosphatase Activity Targets84

Table 28: Cancer Antibody Pipeline Listed by RNA-directed DNA polymerase Activity Targets

Table 29: Cancer Antibody Pipeline Listed by Serine-type Peptidase Activity Targets

Table 30: Cancer Antibody Pipeline Listed by T cell Receptor Activity Targets

Table 31: Cancer Antibody Pipeline Listed by Translation Regulator Activity Targets

Table 32: Cancer Antibody Pipeline Listed by Transmembrane Receptor Activity Targets

Table 33: Cancer Antibody Pipeline Listed by Transmembrane Receptor Protein Tyrosine Kinase Activity Targets

Table 34: Cancer Antibody Pipeline Listed by Transporter Activity Targets

Table 35: Cancer Antibody Pipeline Listed by Unclassified Targets

Table 36: Antibody Drugs Targeting Signaling Pathways

Table 37: Signaling Pathway Analysis of Oncology Antibody Drug Targets

Table 38: Targets Linking Antibody Drugs to the Alpha6 Beta4 Integrin Signaling Pathway

Table 39: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Alpha6 Beta4 Integrin Signaling Pathway

Table 40: Targets Linking Antibody Drugs to the Androgen Receptor Signaling Pathway

Table 41: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Androgen Receptor Signaling Pathway

Table 42: Targets Linking Antibody Drugs to the B Cell Receptor Signaling Pathway

Table 43: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the B Cell Receptor Signaling Pathway

Table 44: Targets Linking Antibody Drugs to the EGFR1 Signaling Pathway

Table 45: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the EGFR1 Signaling Pathway

Table 46: Targets Linking Antibody Drugs to the IL-2 Signaling Pathway

Table 47: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-2 Signaling Pathway

Table 48: Targets Linking Antibody Drugs to the IL-4 Signaling Pathway

Table 49: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-4 Signaling Pathway

Table 50: Targets Linking Antibody Drugs to the IL-6 Signaling Pathway

Table 51: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-6 Signaling Pathway

Table 52: Targets Linking Antibody Drugs to the Kit Receptor Signaling Pathway

Table 53: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Kit Receptor Signaling Pathway

Table 54: Targets Linking Antibody Drugs to the Notch Signaling Pathway

Table 55: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Notch Signaling Pathway

Table 56: Targets Linking Antibody Drugs to the T Cell Receptor Signaling Pathway

Table 57: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the T Cell Receptor Signaling Pathway

Table 58: Targets Linking Antibody Drugs to the TGF-beta Receptor Signaling Pathway

Table 59: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the TGF-beta Receptor Signaling Pathway

Table 60: Targets Linking Antibody Drugs to the TNF-alpha Signaling Pathway

Table 61: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the TNF-alpha Signaling Pathway

Table 62: Targets Linking Antibody Drugs to the Wnt Signaling Pathway

Table 63: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Wnt Signaling Pathway

Table 64: Cell Surface Markers of Identified Cancer Stem Cells in Human Tumors

Table 65: Signaling Pathways Involved in Stem Cell Self-Renewal

Table 66: Immunoconjugated Antibody Targets According to Molecular Function of Target

Table 67: Immunoconjugated Antibody Pipeline According to Target

Table 68: Antibodies in Oncology Reported to Affect Angiogenesis

Table 69 Antibodies in Oncology Reported to Affect Apoptosis

Table 70: Antibody Drug Protein Kinase Targets Ranked by Probability of Carrying at Least One Driver Mutation, Conditional on the Gene-Specific Selection Pressures

Table 71: Antibodies in Oncology Reported to Act as Protein Kinase Inhibitors

Table 72: Cancer Indicaions by Number of Known Antibody Targets, Number of Antibody Drugs, and Highest Developmental Stage

Table 73: Antibody Pipeline by Targets in Basal Cell Cancer

Table 74: Antibody Pipeline by Targets in Biliary Cancer

Table 75: Antibody Pipeline by Targets in Bladder Cancer

Table 76: Antibody Pipeline by Targets in Bone Cancer

Table 77: Antibody Pipeline by Targets in Brain Cancer

Table 78: Antibody Pipeline by Targets in Breast Cancer

Table 79: Antibody Pipeline by Targets in Cervical Cancer

Table 80: Antibody Pipeline by Targets in Cervical Dysplasia

Table 81: Antibody Pipeline by Targets in Colorectal Cancer

Table 82: Antibody Pipeline by Targets in Endometrial Cancer

Table 83: Antibody Pipeline by Targets in Esophageal Cancer

Table 84: Antibody Pipeline by Targets in Fallopian Tube Cancer

Table 85: Antibody Pipeline by Targets in Gastrointestinal Cancers

Table 86: Antibody Pipeline by Targets in Head and Neck Cancer

Table 87: Antibody Pipeline by Targets in Leukemias

Table 88: Antibody Pipeline by Targets in Liver Cancer

Table 89: Antibody Pipeline by Targets in Lung Cancers

Table 90: Antibody Pipeline by Targets in Lymphomas

Table 91: Antibody Pipeline by Targets in Melanoma

Table 92: Antibody Pipeline by Targets in Mesothelioma

Table 93: Antibody Pipeline by Targets in Myelodysplastic syndrome

Table 94: Antibody Pipeline by Targets in Myelomas

Table 95: Antibody Pipeline by Targets in Nasopharyngeal Cancer

Table 96: Antibody Pipeline by Targets in Oesophageal Cancer

Table 97: Antibody Pipeline by Targets in Ovarian Cancer

Table 98: Antibody Pipeline by Targets in Pancreatic Cancer

Table 99: Antibody Pipeline by Targets in Peritoneal Cancer

Table 100: Antibody Pipeline by Targets in Prostate Cancer

Table 101: Antibody Pipeline by Targets in Renal Cancers

Table 102: Antibody Pipeline by Targets in Sarcomas

Table 103: Antibody Pipeline by Targets in Thyroid Cancer

Table 104: Expression Profiles of Antibody Drug Targets in Oncology

Table 105: ALL Classification

Table 106: Latest Approved Drugs for the Treatment of Leukemia

Table 107: Kinase Inhibitors in Development for the Treatment of Leukemia

Table 108: Near Term Progress Rituximab

Table 109: Near Term Progress Oblimersen

Table 110: Near Term Progress Alvocidib

Table 111: Near Term Progress ATRA

Table 112: Near Term Progress GVAX

Table 113: Near Tearm Progress HuM195

Table 114: Near Term Progress Zarnestra

Table 115: Near Term Progress Sorafenib

Table 116: Near Term Progress Valspodar

Table 117: Summary of Current Late Stage Pipeline

Table 118: Near Term Progress CEP-701

Table 119: Near Term Progress PKC412

Table 120: Near Term Progress SU5416

Table 121: Near Term Progress PTK787

Table 122: Near Term Progress VNP40101M

Table 123: Near Term Progress Troxacitabine

Table 124: Near Term Progress Decitabine

Table 125 Near Term Progress Bortezomib

Table 126 Near Term Progress AG-858

Table 127: Near Term Progress bevacizumab

Table 128: Near Term Progress OSI-461

Table 129: Near Term Progress Xcytrin

Table 130: Near Term Progress AP23573

Table 131: Summary of Current Early Stage Pipeline

Table 132 Drugs used in the treatment of lymphoma.

Table 133 Summary of Strategies Enhancing Antibody Function

Table 134 Cancer immunotherapy strategies.

Table 135 Protein Kinase Targets in Clinical Trials for Lymphoma

Table 136 Recent published studies Aldesleukin

Table 137 Recent published studies Arsenic trioxide

Table 138 Recent published studies BiovaxID

Table 139 Recent published studies Bortezomib

Table 140 Recent published studies epratuzumab

Table 141 Recent published studies FavId

Table 142 Recent published studies MyVax

Table 143 Recent published studies Nelarabine

Table 144 Recent published studies Genasense

Table 145 Recent published studies Pixantrone

Table 146 Recent published studies temsirolimus

Table 147 Recent published studies Zanolimumab

Table 148 Recent published studies Flavopiridol

Table 149 Recent published studies bevacizumab

Table 150 Recent published studies CMC-544

Table 151 Recent published studies galiximab

Table 152 Recent published studies LY317615

Table 153 Recent published studies SGN-40

Table 154 Recent published studies Apolizumab

Table 155 Recent published studies SGN-30

Table 156 Accentia BioPharmaceuticals’ Anticancer Pipeline

Table 157 Biogen-Idec’s Anticancer Pipeline

Table 158 Cell Therapeutics’ Anticancer Pipeline

Table 159 Cephalon’s Anticancer Pipeline

Table 160 Chiron´s Anticancer Pipeline

Table 161 Eli Lilly’s Anticancer Pipeline

Table 162 Favrille anticancer pipeline

Table 163 Genentech’s Anticancer Pipeline

Table 164Genitope’s Anticancer Pipeline

Table 165 Genmab’s Anticancer Pipeline

Table 166 Genta’s Anticancer Pipeline

Table 167 GlaxoSmithKline’s Anticancer Pipeline

Table 168 Immunomedics’ Anticancer Pipeline

Table 169 Inex Pharmaceuticals’ Anticancer Pipeline

Table 170 Millennium Pharmaceuticals’ Anticancer Pipeline

Table 171 Protein Design Labs’ Anticancer Pipeline

Table 172 Roche’s Anticancer Pipeline

Table 173 Sanofi-Aventis anticancer pipeline

Table 174 Seattle Genetics’ Anticancer Pipeline

Table 175 Wyeth’s Anticancer Pipeline

3.3 List of Boxes

Box 1: Major treatment regimes

Box 2: CLL staging system

Box 3: Updated REAL/WHO Classification for B-Cell Neoplasms

Box 4: Quick Facts - Clofarabine

Box 5: Quick Facts - Alemtuzumab

Box 6: Quick Facts - Gemtuzumab

Box 7: Quick Facts - Imatinib

Box 8: Quick Facts - Rituximab

Box 9: Quick Facts - Genasense

Box 10: Quick Facts - Flavopiridol

Box 11: Quick Facts - Atra

Box 12: Quick Facts - Gvax

Box 13: Quick Facts - Zarnestra

Box 14: Quick Facts - BAY 43-9006

Box 15: Quick Facts - Ceplene

Box 16: Quick Facts - Valspodar

Box 17: Quick Facts - CEP-701

Box 18: Quick Facts - PKC412

Box 19: Quick Facts - SU5416

Box 20: Quick Facts - PTK787

Box 21: Quick Facts - Cloretazine

Box 22: Company statement on progress

Box 23: Quick Facts - Troxacitabine

Box 24: Quick Facts - FK228

Box 25: Quick Facts - Decitabine

Box 26: Quick Facts - VELCADE

Box 27: Velcade sales 2005

Box 28: Quick Facts - AG-858

Box 29: Quick Facts - Avastin

Box 30: Quick Facts - OSI-461

Box 31: Quick Facts - Xcytrin

Box 32: Quick Facts - AP23573

Box 33 Possible Complications of Treatment

Box 34 Updated REAL/WHO Classification for B-Cell Neoplasms

Box 35 Subclassification of Stage

Box 36 Updated REAL/WHO Classification for B-Cell Neoplasms

Box 37 Updated REAL/WHO Classification for T-Cell and Putative NK-Cell Neoplasms

Box 38 Staging subclassification system

Box 39 Study details

Abstract

In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Antibody drug targets, Leukemias and Lymphomas, which are all subjects to an extensive number of innovative drug candidates. This extensive 430+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in Antibody drug targeting and further give an in depth analysis in two key oncology areas; Leukemia and Lymphoma. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.

There are currently more than 400 antibody based drugs in development for the treatment of cancer. BioSeeker has surveyed these antibodies and identified 132 antibody drug targets, belonging to 220 antibody drugs. In all they range from preclinical development to established therapy leaders in the market place. In total more than 420 clinical trials are included in this analysis, covering more than 30 different cancer indications plus diagnosis and supportive care.

Drug targets and their associated antibodies have been analyzed by BioSeeker according to:

• 34 Different molecular functions of target
• 13 Major signaling pathways
• Cancer stem cells
• Conjugated antibodies
• Therapeutic effects: Anti-angiogenesis, Apoptosis and Protein Kinase Inhibition
• 31 Targeted cancer indications
• Availability of expression profiles of targets in human tissues, cancer tissues, established cell lines and primary cell cultures
• Antibody therapeutic companies

Gain insight into the current challenges and commercial opportunities associated with leukemia and Lymphoma therapy. Explore the strengths and weaknesses associated with compounds in clinical development and the scientific rationale for most novel therapeutics in leukemia and Lymphoma R&D.

Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. And even though a high level of unmet medical need, together with its dependence on chemotherapy, leukemia has not historically been the focus of significant R&D investment for emerging drugs in the pharmaceutical industry. In this report, BioSeeker does not only describe and analyze the latest years of progress in four different market segments; CLL, CML ALL and AML, but also provide an insight and framework to understand the complex field of leukemia therapeutics. provide one of the most comprehensive coverage of the R&D trends to set the future leukemia marketplace. BioSeeker presents both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions on drugs and targets. We have identified 85 drug candidates in phase II or III stage of development and more than 50 companies are involved in the development of these drugs.

Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. The two main groups of lymphoma in humans are Hodgkin’s disease (characterized by the growth of Reed-Sternberg cells) and the non-Hodgkin’s lymphoma (NHL). The lymphoma market is a complex topic and several pitfalls await actors not well prepared. BioSeeker Group will guide thru this field and bring structure and knowledge enables our customers to analyze opportunities. This report will help to answer questions on the subject of additional lymphoma treatments beyond Rituxan.

Already today it is clear that rituximab has generated substantial revenues for the companies involved in its development. A collection of emerging facts suggest that numerous of the new targeted therapies are agents that cannot just be added into treatment regimens with conventional drugs. A few of them might have isolated properties on certain biologic targets that may require to be modulated in particular ways before or after cytotoxic chemotherapy. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.